Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer. (2006). Farmeconomia. Health Economics and Therapeutic Pathways, 7(2), 97-117. https://doi.org/10.7175/fe.v7i2.680